Strategic expansion Novum’s long-standing position as a CRO with early and late phase capabilities, regional presence in multiple U.S. sites, and recent high-profile conference activity indicate opportunities to expand into partner programs or co-development deals with mid-to-large pharma seeking integrated clinical trial solutions.

Clinical capabilities Strong early-phase offerings (FIH/SAD/MAD, BA/BE, PK-PD, special populations) combined with dedicated late-phase trials suggest a compelling value proposition for sponsors aiming to accelerate first-in-human studies and seamless transition into later-stage trials under a single vendor.

Quality and leadership Awards for capability, quality, and reliability, along with leadership changes (new President/COO) and a experienced senior management team, position Novum as a trustworthy partner for risk-averse sponsors prioritizing quality, compliance, and project execution excellence.

Market visibility Active participation in major industry events (AAD, CPHI, SCOPE, JP Morgan) signals intent to engage new clients and build strategic relationships; sales teams can leverage these appearances to source RFPs, partnerships, and multi-study programs.

Financial opportunity Mid-range revenue size (25–50 million) with global CRO peers in the market implies a target for growth through expanded study scopes, cross-sale of early and late-phase services, and pursuing mid-size sponsors seeking scalable CRO partnerships with turnkey solutions.